Joachim Drevs
Joachim Drevs | |
|---|---|
| Born | August 16, 1966 |
| Education | University of Göttingen |
| Medical career | |
| Profession | Physician |
| Institutions | University of Tübingen, University Medical Center Freiburg, Icahn School of Medicine at Mount Sinai |
| Sub-specialties | Oncology |
| Research | Combination chemotherapy |
Joachim Drevs (born August 16, 1966) is a German medical specialist in internal medicine with a focus on hematology and oncology, as well as a university professor at the University Medical Center Freiburg and former leader of the Health Center at the University Clinic in Tübingen.
Life[edit]
Drevs began studying human medicine at the Georg-August University in Göttingen in 1987. There he passed the state examination in 1994 and earned his doctorate under Clemens Unger. He received his medical license in March 1995. Afterwards he was engaged abroad furthering his specialization in oncology at the Klinik Bircher Foundation in Switzerland, at the Mount Sinai Hospital in New York, at the Sefako Makgatho Health Sciences University Clinic in South Africa. In 2005, he earned his postdoctoral qualification at the University Medical Center Freiburg in Freiburg, and in 2009 he was appointed as an adjunct professor at the same clinic. Today he is director of private clinic UNIFONTIS near Braunschweig, Germany and Majorca, Spain.
Clinical focus[edit]
In Tübingen, Drevs established the first university health center in Germany, where the treatment of disease and the promotion of health were offered and practiced together. He concentrated on the implementation of new and innovative therapeutic treatments developed through clinical research on cancer and their clinical applications.
Research[edit]
Drevs has conducted research on the topic of angiogenesis, and was present during the making of a new group of medications for the treatment of tumor patients called Molecular Targeted Therapy. He has also carried out research projects with James F. Holland, Gerd Nagel, and Hubert Blum.[1][2][3]
References[edit]
- ^ Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model. Joachim Drevs, Inga Hofmann, Harald Hugenschmidt, Christine Wittig, Helmut Madjar, Marianne Müller, Jeanette Wood, Georg Martiny-Baron, Clemens Unger and Dieter Marmé. Cancer Res September 1, 2000 (60) (17) 4819-4824;
- ^ Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors. Joachim Drevs, Patrizia Siegert, Michael Medinger, Klaus Mross, Ralph Strecker, Ute Zirrgiebel, Jan Harder, Hubert Blum, Jane Robertson, Juliane M. Jürgensmeier, Thomas A. Puchalski, Helen Young, Owain Saunders, and Clemens Unger. Journal of Clinical Oncology 2007 25:21, 3045-3054;
- ^ PTK787/ZK 222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging. Joachim Drevs, Ralph Müller-Driver, Christine Wittig, Stefan Fuxius, Norbert Esser, Harald Hugenschmidt, Moritz A. Konerding, Peter R. Allegrini, Jeanette Wood, Jürgen Hennig, Clemens Unger and Dieter Marmé. Cancer Res July 15, 2002 (62) (14) 4015-4022;
External links[edit]
- publications of Joachim Drevs on PubMed
- publications of Joachim Drevs on PubFacts
- publications auf Google Scholar
- CV Archived 2017-12-01 at the Wayback Machine
- Joachim Drevs on Facebook
- recent clinic
| International | |
|---|---|
| National | |
